|
1
|
Freeman F, Burdis R and Kelly DJ: Printing
new bones: From print-and-implant devices to bioprinted bone organ
precursors. Trends Mol Med. 27:700–711. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Arealis G and Nikolaou VJ: Bone printing:
New frontiers in the treatment of bone defects. Injury 46 Suppl.
8:S20–S22. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Tateishi-Yuyama E, Matsubara H, Murohara
T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto
K, Akashi H, et al: Therapeutic angiogenesis for patients with limb
ischaemia by autologous transplantation of bone-marrow cells: A
pilot study and a randomised controlled trial. Lancet. 360:427–435.
2002.PubMed/NCBI View Article : Google Scholar
|
|
4
|
McLaughlin KI, Milne TJ, Zafar S,
Zanicotti DG, Cullinan MP, Seymour GJ and Coates DE: The in vitro
effect of VEGF receptor inhibition on primary alveolar osteoblast
nodule formation. Aust Dent J. 65:196–204. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Moses MA: The regulation of
neovascularization of matrix metalloproteinases and their
inhibitors. Stem Cells. 15:180–189. 1997.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Holmes K, Roberts OL, Thomas AM and Cross
MJ: Vascular endothelial growth factor receptor-2: Structure,
function, intracellular signalling and therapeutic inhibition. Cell
Signal. 19:2003–2012. 2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Risau W: Mechanisms of angiogenesis.
Nature. 386:671–674. 1997.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Herzog C, Haun RS, Shah SV and Kaushal GP:
Proteolytic processing and inactivation of CCL2/MCP-1 by meprins.
Biochem Biophys Rep. 8:146–150. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Whelan DS, Caplice NM and Clover AJP:
Mesenchymal stromal cell derived CCL2 is required for accelerated
wound healing. Sci Rep. 10(2642)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tu MM, Abdel-Hafiz HA, Jones RT, Jean A,
Hoff KJ, Duex JE, Chauca-Diaz A, Costello JC, Dancik GM, Tamburini
BAJ, et al: Inhibition of the CCL2 receptor, CCR2, enhances tumor
response to immune checkpoint therapy. Commun Biol.
3(720)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Anada T, Pan CC, Stahl AM, Mori S, Fukuda
J, Suzuki O and Yang Y: Vascularized Bone-mimetic hydrogel
constructs by 3D bioprinting to promote osteogenesis and
angiogenesis. Int J Mol Sci. 20(1096)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Cao Z, Hao Z, Xin M, Yu L, Wang L, Zhang
Y, Zhang X and Guo X: Endogenous and exogenous galectin-3 promote
the adhesion of tumor cells with low expression of MUC1 to HUVECs
through upregulation of N-cadherin and CD44. Lab Invest.
98:1642–1656. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Farrell AS and Sears RC: MYC degradation.
Cold Spring Harb Perspect Med. 4(a014365)2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hu K and Olsen BR: Osteoblast-derived VEGF
regulates osteoblast differentiation and bone formation during bone
repair. J Clin Invest. 126:509–526. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Loirand GJPr: Rho kinases in health and
disease: From basic science to translational research. Pharmacol
Rev. 67:1074–1095. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Pai SG, Carneiro BA, Mota JM, Costa R,
Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK and Giles FJ:
Wnt/beta-catenin pathway: Modulating anticancer immune response. J
Hematol Oncol. 10(101)2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Pompura SL and Dominguez-Villar M: The
PI3K/AKT signaling pathway in regulatory T-cell development,
stability, and function. J Leukoc Biol 2018 (Epub ahead of
print).
|
|
18
|
Roskoski R Jr: ERK1/2 MAP kinases:
Structure, function, and regulation. Pharmacol Res. 66:105–143.
2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lu H, Liu Y, Guo J, Wu H, Wang J and Wu G:
Biomaterials with antibacterial and osteoinductive properties to
repair infected bone defects. Int J Mol Sci. 17(334)2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Stahl A and Yang YP: Regenerative
approaches for the treatment of large bone defects. Tissue Eng Part
B Rev. 27:539–547. 2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhu S, Bennett S, Kuek V, Xiang C, Xu H,
Rosen V and Xu J: Endothelial cells produce angiocrine factors to
regulate bone and cartilage via versatile mechanisms. Theranostics.
10:5957–5965. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kusumbe AP, Ramasamy SK and Adams RH:
Coupling of angiogenesis and osteogenesis by a specific vessel
subtype in bone. Nature. 507:323–328. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhu S, Yao F, Qiu H, Zhang G, Xu H and Xu
J: Coupling factors and exosomal packaging microRNAs involved in
the regulation of bone remodelling. Biol Rev Camb Philos Soc.
93:469–480. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Street J, Winter D, Wang JH, Wakai A,
McGuinness A and Redmond HP: Is human fracture hematoma inherently
angiogenic? Clin Orthop Relat Res. 378:224–237. 2000.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Stuttfeld E and Ballmer-Hofer K: Structure
and function of VEGF receptors. IUBMB Life. 61:915–922.
2009.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Simons M, Gordon E and Claesson-Welsh L:
Mechanisms and regulation of endothelial VEGF receptor signalling.
Nat Rev Mol Cell Biol. 17:611–625. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nelson WJ and Nusse R: Convergence of Wnt,
beta-catenin, and cadherin pathways. Science. 303:1483–1487.
2004.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Blaschuk OW: N-cadherin antagonists as
oncology therapeutics. Philos Trans R Soc Lond B Biol Sci.
370(20140039)2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sabatini PJ, Zhang M, Silverman-Gavrila R,
Bendeck MP and Langille BL: Homotypic and endothelial cell
adhesions via N-cadherin determine polarity and regulate migration
of vascular smooth muscle cells. Circ Res. 103:405–412.
2008.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Tomita K, van Bokhoven A, van Leenders GJ,
Ruijter ET, Jansen CF, Bussemakers MJ and Schalken JA: Cadherin
switching in human prostate cancer progression. Cancer Res.
60:3650–3654. 2000.PubMed/NCBI
|
|
32
|
Heasman SJ and Ridley AJ: Mammalian Rho
GTPases: New insights into their functions from in vivo studies.
Nat Rev Mol Cell Biol. 9:690–701. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
33
|
Dong M, Yan BP, Liao JK, Lam YY, Yip GW
and Yu CM: Rho-kinase inhibition: A novel therapeutic target for
the treatment of cardiovascular diseases. Drug Discov Today.
15:622–629. 2010.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lock FE and Hotchin NA: Distinct roles for
ROCK1 and ROCK2 in the regulation of keratinocyte differentiation.
PLoS One. 4(e8190)2009.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wu YJ, Tang Y, Li ZF, Li Z, Zhao Y, Wu ZJ
and Su Q: Expression and significance of Rac1, Pak1 and Rock1 in
gastric carcinoma. Asia Pac J Clin Oncol. 10:e33–e39.
2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lou Z, Billadeau DD, Savoy DN, Schoon RA
and Leibson PJ: A role for a RhoA/ROCK/LIM-kinase pathway in the
regulation of cytotoxic lymphocytes. J Immunol. 167:5749–5757.
2001.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Noma K, Rikitake Y, Oyama N, Yan G,
Alcaide P, Liu PY, Wang H, Ahl D, Sawada N, Okamoto R, et al: ROCK1
mediates leukocyte recruitment and neointima formation following
vascular injury. J Clin Invest. 118:1632–1644. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
38
|
Lock FE, Ryan KR, Poulter NS, Parsons M
and Hotchin NA: Differential regulation of adhesion complex
turnover by ROCK1 and ROCK2. PLoS One. 7(e31423)2012.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Dang CV, O'Donnell KA, Zeller KI, Nguyen
T, Osthus RC and Li F: The c-Myc target gene network. Semin Cancer
Biol. 16:253–264. 2006.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Baudino TA, McKay C, Pendeville-Samain H,
Nilsson JA, Maclean KH, White EL, Davis AC, Ihle JN and Cleveland
JL: c-Myc is essential for vasculogenesis and angiogenesis during
development and tumor progression. Genes Dev. 16:2530–2543.
2002.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Peiris TH, Ramirez D, Barghouth PG and
Oviedo NJ: The Akt signaling pathway is required for tissue
maintenance and regeneration in planarians. BMC Dev Biol.
16(7)2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Abeyrathna P and Su Y: The critical role
of Akt in cardiovascular function. Vascul Pharmacol. 74:38–48.
2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Radisavljevic Z: AKT as locus of cancer
phenotype. J Cell Biochem. 116:1–5. 2015.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Zhai H, Pan T, Yang H, Wang H and Wang Y:
Cadmium induces A549 cell migration and invasion by activating ERK.
Exp Ther Med. 18:1793–1799. 2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Gough NR: Focus issue: Recruiting players
for a game of ERK. Sci Signal. 4(eg9)2011.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Liu P and Zhong TP: MAPK/ERK signalling is
required for zebrafish cardiac regeneration. Biotechnol Lett.
39:1069–1077. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Lin F, Chengyao X, Qingchang L, Qianze D,
Enhua W and Yan W: CRKL promotes lung cancer cell invasion through
ERK-MMP9 pathway. Mol Carcinog 54 Suppl. 1:E35–E44. 2015.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Gillard JA, Reed MW, Buttle D, Cross SS
and Brown NJ: Matrix metalloproteinase activity and
immunohistochemical profile of matrix metalloproteinase-2 and -9
and tissue inhibitor of metalloproteinase-1 during human dermal
wound healing. Wound Repair Regen. 12:295–304. 2004.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Raeeszadeh-Sarmazdeh M, Do LD and Hritz
BG: Metalloproteinases and their inhibitors: Potential for the
development of new therapeutics. Cells. 9(1313)2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Shi YN, Zhu N, Liu C, Wu HT, Gui Y, Liao
DF and Qin L: Wnt5a and its signaling pathway in angiogenesis. Clin
Chim Acta. 471:263–269. 2017.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Yao L, Sun B, Zhao X, Zhao X, Gu Q, Dong
X, Zheng Y, Sun J, Cheng R, Qi H and An J: Overexpression of Wnt5a
promotes angiogenesis in NSCLC. Biomed Res Int.
2014(832562)2014.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Silvério KG, Davidson KC, James RG, Adams
AM, Foster BL, Nociti FH Jr, Somerman MJ and Moon RT: Wnt/β-catenin
pathway regulates bone morphogenetic protein (BMP2)-mediated
differentiation of dental follicle cells. J Periodontal Res.
47:309–319. 2012.PubMed/NCBI View Article : Google Scholar
|
